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Abstract 
The goal of this study was to determine whether detection of β-HPV gene products, as defined 
in epidermodysplasia verruciformis skin cancer, could also be observed in lesions from kidney 
transplant recipients (KTRs) alongside the viral DNA.  A total of 111 samples, corresponding to 79 
skin lesions abscised from 17 KTRs, have been analyzed. The initial PCR analysis demonstrated 
that β-HPV-DNA was highly present in our tumor series (85%). Using a combination of antibodies 
raised against the E4 and L1 proteins of the β-genotypes, we were able to visualize productive 
infection in 4 out of 19 actinic keratoses, and in the pathological borders of 1 out of 14 squamous 
cell carcinomas and 1 out of 31 basal cell carcinomas. Increased expression of the cellular 
proliferation marker MCM7, that extended into the upper epithelial layers, was a common feature of 
all the E4-positive areas, indicating that cells were driven into the cell cycle in areas of productive 
viral infections. Although the present study does not directly demonstrate a causal role of these 
viruses, the detection of E4 and L1 positivity in actinic keratosis and the adjacent pathological 
epithelium of skin cancer, clearly shows that β-HPV are actively replicating in the intraepidermal 
precursor lesions of KTRs and can therefore cooperate with other carcinogenic agents, such as 
UVB, favoring skin cancer promotion. 
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Introduction 
Solid organ transplantation is a treatment offered to an increasing number of patients with 
end-stage organ diseases. Although life-saving, organ transplantation is associated with an overall 
3-5 fold increased risk of malignancies.1–4  Most of these cancers are caused by reactivated viruses 
whose oncogenic potential is suppressed by immunological reactions in healthy individuals, like 
Epstein-Barr virus-associated B-cell lymphomas, Kaposi’s sarcoma, caused by the reactivation of 
human Herpesvirus type 8, and Merkel cell carcinomas (MCC) of the skin, associated with Merkel 
cell polyomavirus (MCPyV or MCV).5–9 
Of the cancers presenting in organ transplant recipients (OTRs) that have no established 
infectious etiology, skin cancer is the most frequent form (95%), including non-melanoma skin 
cancers (NMSC); squamous cell and basal cell carcinomas in particular (SCC and BCC, 
respectively).10–13 The incidence of NMSC, the most common cancer in fair-skinned populations, is 
at least 50-fold higher in OTRs.14–16 Large numbers of skin tumors (often more than ten) tend to 
develop over time in these at-risk subjects, thus presenting an enormous challenge for the patients 
and those responsible for their care.17,18 
Nearly all adults are persistently infected in the skin with many viruses belonging to the Human 
Papillomavirus (HPV) family.19,20 Although they appear not to cause overt clinical symptoms in a 
great majority of infected individuals, they can cause cancer, either in skin or in genital sites, 
particularly in subjects with impaired immune function.21–25 To date, more than 150 HPV types 
have been completely sequenced and classified into five genera (and a number a species within each 
genus) based on DNA sequence analysis.26,27 Of these, Alphapapillomaviruses (α-HPVs) are 
associated with genital cancer (e.g. HPV16 and 18) and some genotypes with common skin warts.28 
Skin-tropic Betapapillomaviruses (β-HPVs) (e.g. HPV5 and 8) are evolutionarily distinct from 
genus Alpha and appear to cause widespread unapparent or asymptomatic infections in the general 
population, but they have been associated with skin cancer in the immunocompromised host.29 
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The relationship between β-HPV infection and NMSC has been clearly defined in patients 
suffering from the rare inherited disease epidermodysplasia verruciformis (EV), an autosomal 
recessive disease characterized by a predisposition to infection by specific types of β-HPV.30–32 In 
these patients, HPV5 and 8 replicate very efficiently and reveal their full transforming potential, 
inducing multiple NMSC.33,34 
Emerging evidence also supports the role of β-HPV in skin cancer development in 
immunosuppressed individuals. Sero-epidemiological studies have associated NMSC in OTRs with 
the presence of anti-β-HPV antibodies, and PCR-based studies have identified β-HPV DNA in over 
80% of skin tumors from these patients.22,35–43 Despite these findings, a causal role of these viruses 
has been difficult to verify because of their ubiquitous prevalence in the general population and 
their absence in some cancers.25,44 The major weakness of the available studies is that the proposed 
association is mostly based on the presence of viral DNA in tumor tissues or positive antibody 
responses. Very few studies have addressed whether the β-HPV detected in these cases are actually 
localized within the malignant cells or whether they are transcriptionally active, the confirmation of 
which would greatly strengthen the evidence for a carcinogenic role of these pathogens. 
In a recent study, we examined the β-ΗPV life cycle in skin tumors obtained from EV 
patients and found that, similar to what has been seen with other PV types, the onset of vegetative 
viral genome amplification coincides closely with the cytoplasmic expression of the viral protein E4 
during productive infection.33 This pattern was observed in all areas of the tumors where there was 
still some morphological differentiation of the epithelium. In addition, we have also demonstrated 
using fluorescent in situ hybridization (FISH) that the abundance of β-HPV seen in some lesions 
was a direct result of genome amplification within the carcinoma tissue.34 Overall, our results 
indicated that E4 staining could be exploited as a marker of viral expression during β-HPV-
associated skin cancer progression as reported in the HPV8 transgenic mouse model and in cervical 
disease for the alpha genotypes.33,45-47  
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In order to extend the data obtained so far in EV patients to other groups of patients at high 
risk of developing NMSC, here we studied a series of skin lesions from kidney transplant recipients 
(KTRs) attending our University Hospital by systematically analyzing for the presence of β-HPV 
infection both at the DNA (PCR) and protein level. Using a combination of antibodies raised 
against the E4 and L1 proteins of the β-genotypes, we were able to visualize the completion of viral 
life cycle in some precancerous lesions such as actinic keratosis or at the periphery of more 
advanced disease. These data demonstrate that β-HPV transcription is occurring at site of skin 
transformation in the OTR setting and points to its possible involvement in the process of skin 
carcinogenesis.  
 
Material and Methods 
Sample collection.  
Tissue sections were obtained from 111 formalin-fixed and paraffin-embedded (FFPE) 
blocks, previously collected from 79 skin lesions and stored in the University Hospital medical 
material archives. For some lesions, only a single block was available, denominated ‘whole lesion’ 
(WL); while for others, two blocks existed, corresponding to the core (C) and edges (E) of the 
lesion. All lesions were excised from 17 KTRs, while one amongst them was also heart-transplant 
twice, (16 male and 1 female) receiving transplants between 1998 and 2009. Data on skin lesion 
development and characteristics were retrieved from pathology archives and clinical records. The 
mean length of patient follow-up following kidney transplantation was 15 years and 4 months ± 7 
years and 8 months. A single FFPE block from a wart-like lesion of a patient with 
epidermodysplasia verruciformis was also analyzed in the present study as positive control.  
Written informed consent was obtained by all subjects according to the Declaration of 
Helsinki and approval was obtained from local ethic committee. 
β-HPV DNA detection and genotyping with the PM-PCR RHA method 
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Two consecutive 10 μm-thick sections were retrieved from FFPE samples and used to 
extract DNA by means of the QIAamp Tissue Kit (Qiagen srl, Milan, Italy) according to the 
manufacturer’s instructions. To prevent cross-contamination, the microtome was thoroughly 
cleaned following the sectioning of each block and a new blade installed for the next. β-HPV 
detection and genotyping was carried out using the PM-PCR reverse hybridization assay (RHA) 
method (Skin β-HPV prototype research assay; Diassay BV, Rijswijk, The Netherlands), as 
previously described.48 The method was designed to identify the 25 established β-HPV types (i.e., 
HPV genotypes 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 
93, and 96). The PM-PCR reverse hybridization assay, which generated a biotinylated amplimer of 
117 bp from the E1 region, was carried out following all the precautions indicated by the 
manufacturer to avoid recurrence of cross-contamination. Briefly, PM-PCR was performed in a 
final reaction volume of 50µL, containing 10µL of the isolated DNA, 2.5mM MgCl2, 1x GeneAmp 
PCR buffer II, 0.2mM deoxynucleoside triphosphates, 1.5 U Amplitaq Gold DNA polymerase and 
10µL of the PM primer mix. The PCR was performed by a 9 min preheating step at 94oC, followed 
by 35 cycles of amplification comprising 30 s at 94oC, 45 s at 52oC, and 45 s at 72oC. PCR was 
ended by a final elongation step of 5 minutes at 72oC. As a positive PCR control, a β-HPV plasmid 
clone was included. Identification of the amplified HPV types was performed by reverse 
hybridization analysis of the amplimers on genotyping strips provided by the manufacturer. In each 
strip a probe line contains a mix of “universal” HPV probes: in some cases these probes are positive 
without a probe for specific β-HPV being positive, indicating the presence of an unspecified β-
HPV. These cases are indicated as ‘unspecified β-papillomavirus genotype’. 
Antibodies and generation of anti-L1 antibodies 
To generate antibodies that can broadly identify the L1 proteins of the β-genotypes, sequence 
alignments were first carried out, and the highly conserved region between amino acid 200 and 300 
was chosen. This region of the HPV5 full length protein (Ref. Seq.: NP_041372.1) was amplified 
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by PCR from an HPV5 genomic clone recently isolated from an EV patient. The primer sequences 
used were: L1 forward: 5´-CGCGGATCCCGTCTGTATCCAAAACCCTTG-3´; L1 reverse: 5´-
CCGCTCGAGTTATCCTATAGTCTTTTGAGCTTG-3´. The forward primers included a BamHI 
site (underlined) upstream of the ATG initiation codon, while the reverse primers contained a XhoI 
sequence (underlined). Amplimers were cloned into the pGEX-4T-2 vector (GE Healthcare Europe 
GmbH, Milan, Italy), and then expressed in the Escherichia coli host BL21. GST-L1 fusion protein 
was dialyzed overnight at 4°C in 50mM Tris-HCl pH 8.5, 0.5% β-mercaptoethanol and 3M urea, 
and then re-dialyzed for 12h at 4°C in 50mM Tris-HCl pH 8.5 and protease inhibitors (Sigma). 
Anti-sera were raised by injecting rabbits with the dialyzed GST-L1 fusion protein. Animals were 
bled 1 week after the fourth immunization and serum immunoglobulins obtained by precipitation 
with 45% saturated ammonium sulfate. The precipitate was then resuspended in phosphate-buffered 
saline (PBS) and purified on a protein A affinity column (GE Healthcare) according to the 
supplier’s specifications. Preimmune serum was collected prior to the initiation of the immunization 
protocol and was used as a control in the immunostaining experiments. 
The production of polyclonal antibodies to HPV5E4, which crossreact with many genotypes 
from species 1, including HPV8, 14, 20, 24, 25, 36, has been described previously.33 Antibodies to 
minichromosome maintenance protein 7 (MCM7) were obtained from Neomarkers Fremont (MS-
862-p1). 
Immunofluorescent detection 
Consecutive 5-μm thick sections obtained from FFPE tissues were processed for 
immunofluorescent detection of antigens coupled to DNA-FISH as previously described.49 For the 
other markers analyzed (E4, MCM7, L1), antigen unmasking was performed by heating the slides 
in a conventional decloaking chamber, where they were placed for 10 min at 121°C in 10 mM 
citrate buffer at pH 6.0 (Vector Laboratories, Burlingame, CA). The immunofluorescent protein-
protein double detection (HPV5 E4-MCM7) was carried out by incubating the slides overnight at 4 
°C with the primary antibody anti-MCM7 (1:200) diluted in 5% normal goat serum (NGS) followed 
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by the amplification with TSA (Tyramide Signal Amplification; Perkin Elmer, Waltham 
MA); then, slides were incubated with the primary antibody anti-HPV5 E4 (1:1000) for 3 hours and 
subsequently with the appropriate fluorescent secondary antibody. The immunofluorescence for L1 
detection was carried out by incubating the slides overnight at 4 °C with the primary antibody anti-
L1 (1:1000) diluted in 5%NGS-PBS followed by incubation with the appropriate fluorescent 
secondary antibody. Images were acquired using a digital scanner (Pannoramic MIDI, 3D Histech 
Kft., Budapest, Hungary). For the assessment of histological features, the slides analyzed by HPV5 
E4-MCM7 were disassembled and stained with hematoxylin and eosin (H&E).  
 
Results 
Patients and skin lesion characteristics 
 The baseline characteristics of the study population and the histological features of the 
cutaneous lesions, alongside the relative number of lesions, the year in which they occurred 
following transplantation, and their location at sun-exposed or unexposed sites are listed in Table 1. 
The median time of skin lesion occurrence was 7±5 years after transplantation. Patients are 
numbered in ascending order based on the number of tumors developed. Within 10 years from 
transplantation, 5 patients developed more than 5 lesions (patients 13 to 17), mostly in sun-exposed 
sites, confirming sun exposure to be a major contributor to epithelial transformation. The skin 
lesions included: SCC (n=14), and BCC (n=31), followed by precancerous lesions such as actinic 
keratosis (n=19) (AK) and Bowen’s disease (n=1) (BD), keratoacanthoma (n=7) (KA), and benign 
lesions such as seborrheic keratosis (n=7) (SK). The proportion of lesions affecting sun-exposed 
skin areas (head, hands and forearms) was 59 out of 79 lesions (75%).  
β-HPV type determination  
The results of β-HPV testing of the DNA extracted from the 79 lesions are shown in Table 
2. In 28 cases, multiple biopsy blocks were available corresponding to either the core or edges of 
the lesions. Out of the 111 FFPE blocks analyzed, 94 were HPV positive (85%), and 86 samples 
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(77%) could be genotyped as containing at least one of the 25 β-HPV genotypes available on the 
RHA (Table 2).  
The spectrum of β genotypes identified for each lesion from the 17 study patients is reported 
in the Supplementary Table 1. In cases of multiple biopsies, the genotypes found in the core and 
edges of the tumors are combined. The most frequently observed genotypes are HPV5 and 8 (both 
belonging to species 1), which were found in 51 (65%) and 20 (25%) of the 79 lesions, respectively. 
HPV5 was detected as a single infection in 18 out of the 79 lesions (23%) and HPV8 was detected 
as a single infection in 2 lesions (3%). Multiple infections with 2 genotypes were found in 13 
lesions (16%), while more than 2 genotypes were found in 28 lesions (35%). In the five patients 
exhibiting more than 5 tumors, HPV5 alone or in multiple infections was found in 38 (66%) of the 
58 lesions present on these 5 patients. Considering just the genotypes belonging to species 1, 
including HPV5, 8, 12, 14, 19, 24, 25, 36 and 93, 61 tumors (77%) turned out to be positive for at 
least one genotype. For the lesions split into more FFPE blocks (n=36), at least one β1 genotype 
was consistently found in 15 (42%) of them (data not shown).  
Visualization of viral protein expression in skin lesions  
Previous studies from our group have demonstrated that detection of the abundant viral E4 
protein is helpful for the visualization of active β-HPV infection in skin tumors from EV 
patients.33,34 Figure 1 shows representative images of tissue sections from a benign wart-like lesion 
from an EV patient displaying the unequivocal histological features associated with the infection, 
including acanthosis and the disorganization of the granular layers defined by an abrupt variation in 
keratoyaline granules. The E4-positive cells are enlarged and display prominent blue-grey pallor 
with occasional perinuclear halos. HPV8 DNA-FISH analysis confirmed that these cells are 
supporting viral genome amplification as visualized by many positive nuclei for overlapping 
cytoplasmic E4 staining. Completion of the viral life cycle was also defined by L1 staining 
performed using in-house polyclonal antibodies raised against a common region of the β-genus 
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major capsid protein. As expected, L1-positive nuclei were detected in the more superficial layers 
of the E4-positive area.50 The cellular proliferation marker MCM7 was also strongly increased in 
the lesion compared with the adjacent normal epithelium; being most apparent in the basal and 
suprabasal layers indicating that cells were stimulated to enter the cell cycle.49,52 
To investigate whether similar images of productive infection could be visualized in OTR 
skin lesions, tissue specimens from the available FFPE blocks were co-stained using 
immunofluorescence (IF) analysis with anti-E4 and anti-L1 antibodies to detect viral antigen 
expression, and with MCM7, a marker of cellular proliferation.  
Out of the 111 FFPE blocks analyzed, E4-positive cells were found in 6 FFPE blocks (for 
brevity, referred to as IF-positive), originating from patients 5, 8, 16, and 17, and corresponding to 4 
AK lesions, and the adjacent pathological area of 1 SCC and 1 BCC. Patients 16 and 17 were 
transplanted in 1993 and 1999, respectively, and developed 14 skin lesions each in their post-
transplant period. The other two patients received transplants in 2002 and 2005, respectively. Table 
3 summarizes all the lesions developed by the IF-positive patients and reports the details of the 
genotyping results for each FFPE block available, distinguishing the different parts of the lesions 
(edges, core or whole lesion). As expected from the spectrum of the polyclonal anti-E4 antibody 
used, all the IF-positive sections harbored genotypes belonging to species 1.  
Having established the EV staining pattern, we carefully went through all the E4-positive 
areas identified in our tumor series, looking for their major histological characteristics and staining 
patterns, and the most representative images are presented. Figure 2 shows one of the two E4-
positive areas detected in the adjacent pathological epithelium from a BCC of the neck. The 
epithelium displays acanthosis and both the E4 and L1 staining patterns show great resemblance to 
those obtained from the EV patient shown in Figure 1. Figure 3 summarizes the staining obtained 
from patient 8, focusing on the positive area found in the bowenoid AK, located next to the SCC. 
This area shows clear signs of β-HPV-related cytopathic effects, some cells display pleomorphism 
and nuclear atypia,  and again both early and late viral markers of β-HPV infection are present. 
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Three hypertrophic AK, from the same patient (patient 16), are reported in Figure 4 (panels 
A-C). Panel A shows a clear-cut area of positivity found in an epithelial crevice, where disruption 
of the granular layer was clearly evident alongside parakeratosis. In this case, it was also possible to 
perform FISH with the single genotype found, specifically HPV25; where FISH-positive nuclei 
neatly overlapped with some E4-positive cells in the cytoplasm, while L1 positivity was confined to 
some parakeratotic nuclei. The positive area reported in panel B was found in the pathological edge 
of an AK and shows the typical staining pattern and cytopathic effects of productive β-HPV 
infection. The AK of panel C shows a positive area corresponding to a highly parakeratotic 
epithelium that abruptly changed to normal orthokeratosis on both sides. As expected from the high 
grade of parakeratosis, many L1-positive nuclei were found above the E4-positive cells. Consistent 
with the staining seen in the EV lesion shown in Figure 1, MCM7 expression was increased in all 
the E4-positive areas, being present in the basal layer and above (see especially Figure 4B). This 
staining decreased following the onset of E4 expression, although a region of overlap was well 
apparent where E4-MCM7 double-positive cells were found.   
A clear area of positivity was also found in the adjacent pathological epithelium of a SCC, 
as reported in Figure 5. Here, the cytopathic effect is remarkable and unequivocally similar to what 
is generally found in intraepidermal precursor lesions from EV patients. Many E4-positive cells are 
present, as well as superficial L1-positive nuclei. Unfortunately, although performed and present, 
we are not able to show FISH-positivity with HPV24 because this slide turned out to be very fragile 
and got severely damaged during processing.  
In addition, the H&E staining of all the tissue sections which were negative for viral markers 
were carefully screened for the signs of any cytophatic effects, while none observed.   
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Discussion 
To our knowledge, this is the first study in which the association between skin lesions and β-
HPV infection has been assessed at both the DNA level by PCR and at the protein level by 
immunofluorescence analysis. The main goal of this study was to determine whether detection of β-
HPV gene products, as defined in skin tumors from EV patients, could also be observed in lesions 
from KTRs. We chose to compare the KTR setting with EV because they share the following two 
main features: i) a status of chronic immunosuppression, which may favor persistence or 
reactivation of latent skin-tropic viruses including β-HPV; and ii) the high risk of developing 
multiple skin cancers.9,10,12 These commonalities are also valid for patients affected by primary 
immunodeficiencies in general.51 In addition, in this study the EV model served as an important tool 
for optimizing the staining procedure with anti-E4 and L1 antibodies, and was used as a positive 
control when examining KTR tissue sections. A polyclonal antibody recognizing the E4 protein 
from species 1 was used alongside a newly generated polyclonal antibody raised against a highly 
conserved region of the L1 protein from the β genus. In addition, to increase the chances of success, 
the biopsy blocks containing the normal surrounding areas of the tumors were also processed for the 
viral markers for a total of 111 FFPE corresponding to 79 skin lesions abscised from 17 KTRs.  
The initial PCR analysis demonstrated that β-HPV-DNA was highly present in our 
specimens, with 94 blocks (85%) resulting positive. Multiple infections were observed in 41 lesions 
(52%), and at least one genotype belonging to the β1 species was found in 79 of the 111 blocks 
analyzed by PCR (71%). 
When we analyzed the same specimens by immunofluorescence, 6 blocks showed areas of 
positivity corresponding to 4 AK, and the adjacent pathological epithelium of 1 BCC, and 1 SCC. 
The E4-positive areas were found in the context of the disorganized epithelium in the AK lesions, 
while in the more advanced tumors, such as SCC and BCC, they were always localized to the 
adjacent pathological epithelium. In all the specimens, the viral E4 protein displayed the expected 
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cytoplasmic localization in the middle-superficial layers of the epithelium accompanied by an 
increase of the cellular proliferation marker MCM7 in the basal and suprabasal layers. The 
disappearance of E4-positivity in the adjacent normal epithelium constantly overlapped with a 
reduction in MCM7 expression, which was restricted to the basal layer. These findings support the 
hypothesis that β-HPV replication drives the cells above the basal layer to enter the cell-cycle in 
order to facilitate the amplification of its genome. Consistent with this observation, FISH-positive 
nuclei for the viral genome were found in some of the E4-positive cells. As further proof that the 
viral life cycle was being completed, all the E4-positive areas showed expression of the major coat 
protein (L1), which also occurred in a subset of E4-positive cells in the upper layers. This is fully 
consistent with what has been seen with other PV types, where the onset of vegetative viral genome 
amplification coincides closely with the expression of cytoplasmic E4 and nuclear L1 in some very 
superficial cells during productive infection.49,50,52 In one highly differentiated AK, the number of 
L1 positive nuclei was very high and most of them were in the thick layers of parakeratosis.  
 A common trait of cancers with a well-documented viral etiology is their high incidence in 
immunosuppressed individuals.5-9 Since skin cancer is the most prevalent tumor in the OTR setting, 
one would expect that viruses may contribute to this well documented increased susceptibility and 
incidence. The discovery and detection of β-HPV-DNA and its active infection in EV patients 
provided an important new insight into the viral oncogenesis of skin cancer which might be 
extendable to other subsets of patients including other primary immunodeficiencies (PIDs) and 
particularly long-lasting iatrogenically immunosuppressed patients, such as OTRs.  Despite many 
efforts, direct evidence of active β-HPV infection in tumors from non-EV patients were still 
missing and the major criticism against a direct involvement of these viruses in skin cancer in the 
general population is that they do not seem to be maintained in high-grade tumors, such as SCC. To 
date, the evidence suggesting a causal role of β-HPV in skin cancer has been tainted by: the finding 
that viral DNA is also found in normal skin, that discovery the viral genome copy number is usually 
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much less than one viral genome per tumor cell, and the fact that viral transcripts have not been 
identified by high-throughput mRNA sequencing.19,53-56 Alongside the fact that ubiquitous β-HPV 
DNA carriage does not necessarily indicate active infection, these issues have created and so far 
maintained a state of uncertainty about the causative role of β-HPVs in non-EV skin cancer. 
Although the present study does not directly demonstrate a causal role of these viruses, the 
detection of E4 and L1 positivity in i) AK, which are widely regarded to be SCC precursors or in 
situ carcinoma, and ii) the adjacent pathological epithelium of 1 SCC and 1 BCC, clearly shows that 
β-HPV are actively replicating in the lesional skin of OTRs and can therefore cooperate with other 
carcinogenic agents, such as UVB, favoring skin cancer promotion and progression.  
Our data are fully consistent with the model proposed by Weissenborn et al. in 2005,54 who 
demonstrated that the highest β-HPV loads are present in AK, rather than in SCC, suggesting that 
their persistence may not be necessary for the maintenance of the malignant phenotype. Instead, 
they may act as a co-factor that enhances the carcinogenic potential of UV damage, as shown by 
Wallace et al.,57 who also demonstrated that β-HPV E6 expression can enhance the carcinogenic 
potential of UV exposure by promoting p300 degradation. 
If β-HPV infections play a role in skin cancer, then they must do so transiently and very 
likely upon reactivation or persistence in the immunocompromised host. Our findings, showing 
active β-HPV infection in precancerous lesions and in the vicinity of malignant tumors, are fully 
compatible with a role of these viruses in the early steps of skin carcinogenesis in at least the 
immunosuppressed setting. These data are consistent with the “hit and run” mechanisms of 
carcinogenesis, with cutaneous HPV being possibly important for tumor initiation and progression 
but not necessary for tumor maintenance.58,59 Consistent with a causal role in the early stage of the 
disease, E4-positivity was clearly visualized in an AK that was localized adjacent to a SCC in the 
neck region. In addition, increased MCM7 expression that extended into the upper epithelial layers 
was a common feature of all the E4-positive areas, indicating that cells were driven into the cell 
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cycle in areas of productive viral infections.23,49,50 The observed stimulation of basal cell 
proliferation may contribute, in association with other transforming agents, such as UVB 
irradiation, to the transformation process without necessarily being maintained in the more 
advanced disease. 
Assuming that viral replication is more active at very early stages of carcinogenesis and 
perhaps when lesions are not yet even clinically evident, thus it is reasonable to propose that when 
lesions are removed, especially in more advance stages, only some residual areas are detectable that 
exhibit viral replication. It is also worth mentioning that the areas of positivity were usually found 
in lesions which were originally split in more than one FFPE blocks. This procedure is currently 
applied when the surgical specimen is quite big and the different areas of the lesion are 
macroscopically evident as it is occurring when the erythematosus area surrounding the tumor is 
also surgically removed. This can also be defined as field cancerization. These assumptions can 
explain the low percentage of positivity found in this kind of study and the need of more thorough 
investigation of the perilesional skin where the likely-hood of finding active β−HPV infection 
should be higher.   
In summary, our work shows that careful detection of β-HPV gene products at the single cell 
level allows us to visualize their sites of replication, especially in intraepidermal precursor lesions 
and the marginal zones of more advanced disease. However, these findings require further research 
to improve our knowledge of β-HPV natural infection and reactivation which will help to 
understand how it is influenced by the epithelial site, UVB exposure, and the immune system.  
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Figure legends 
Figure 1. Distribution of the viral and cellular markers E4, L1, HPV8 DNA, and MCM7 in a 
wart-like lesion from an EV patient (elbow). The top images show the scan of the H&E 
histological staining (left) and IF staining (MCM7 in red; E4 in green) (right) of the same tissue 
section. The white dotted line indicates the basal layer. In the lower panel, the above mentioned 
MCM7/E4 staining is reproduced (left picture) and serial sections were double stained for the 
presence of viral genome amplification by HPV8 DNA-FISH (red) and for E4 expression (green) 
(middle picture); and stained with antibodies to L1 (red) (right picture). The region shown 
corresponds to the red square highlighted in the H&E image. The white arrows indicate nuclear L1 
staining. All sections were counterstained with DAPI (blue) to visualize cell nuclei. Scale bars: 100 
μm.  
 
Figure 2. Distribution of the viral and cellular markers E4, L1, and MCM7 in a basal cell 
carcinoma (BCC) from a KTR (patient 5, neck). The top picture shows the scan of the tissue 
section using H&E staining (scale bar: 1000 μm). The blue circle shows the BCC and the red square 
indicates the area of interest in the adjacent epithelium. The region shown in the lower panels (scale 
bars: 100 μm) corresponds to the red square highlighted in the overall H&E image, magnified in the 
left hand lower panel. In the middle picture, the same section was double stained using antibodies to 
E4 (green) and MCM7 (red),  and a serial section was stained with antibodies to L1 (red) (right 
picture). The white arrows indicate nuclear L1 staining. All sections were counterstained with DAPI 
(blue) to visualize cell nuclei.  
 
Figure 3. Distribution of the viral and cellular markers E4, L1, and MCM7 in a bowenoid 
actinic keratosis (AK) from a KTR (patient 8, neck). The top pictures (scale bars: 1000 μm) 
show the scan of the tissue sections using H&E staining; the right hand panel shows an AK with the 
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area of interest boxed in red and the left panel shows a nearby squamous cell carcinoma (SCC). The 
region shown in the lower panels corresponds to the red square highlighted in the H&E image, 
magnified in the left hand lower picture. The same section was double stained using antibodies to 
E4 (green) and MCM7 (red) (middle picture) and a serial section was stained with antibodies to L1 
(red) (right picture). The white arrows indicate nuclear L1 staining. All sections were 
counterstained with DAPI (blue) to visualize cell nuclei. Scale bars: 50 μm. 
 
Figure 4. Distribution of the viral and cellular markers E4, L1, HPV25 DNA, and MCM7 in 
three cases of hypertrophic actinic keratosis (AK) from a KTR (patient 16, A. hand; B. face; 
C. hand). A: The top picture (scale bar: 1000 μm) shows the scan of the tissue section of the first 
AK using H&E staining. The region shown in the lower panels corresponds to the red square 
highlighted in the over H&E image, reproduced in the lower left hand picture. The same section 
was double stained using antibodies to E4 (green) and MCM (red) (second picture); serial sections 
were double stained for the presence of viral genome amplification by HPV25 DNA-FISH (red) and 
for E4 expression (green) (third picture); and also stained with antibodies to L1 (red) (fourth 
picture). The white arrows indicate nuclear L1 staining. All sections were counterstained with DAPI 
(blue) to visualize cell nuclei. Scale bars: 50 μm) B: The top pictures (scale bars: 1000 μm) show 
the scan of the tissue sections (using H&E staining) of the second AK (left picture) and its edge 
(right picture). The right handed middle panel shows the histology (H&E staining) of the area from 
the edge where viral markers were expressed (red square) and an overall picture of the IF staining 
(E4 in green; MCM7 in red) of the same tissue section (scale bars: 200 μm). The white dotted line 
indicates the basal layer. In the lower panel, the above MCM7/E4 staining is reproduced (left 
picture) and serial sections were stained with antibodies to L1 (red) (right picture). The white 
arrows indicate nuclear L1 staining. Scale bars: 100 μm. All sections were counterstained with 
DAPI (blue) to visualize cell nuclei. C: The top picture shows the scan of the tissue section of the 
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third AK using H&E staining (scale bar: 1000 μm). The black rectangle shows a magnification 
(scale bar: 400 μm) of the positive parakeratotic epithelium that abruptly changed to normal 
orthokeratosis on both sides. The region shown in the lower panels corresponds to the red square 
highlighted in the H&E image, reproduced in the lower left hand picture. The same section was 
double stained using antibodies to E4 (green) and MCM7 (red) (middle picture) and a serial section 
was stained with antibodies to L1 (red) (right picture). Scale bars: 50 μm). All sections were 
counterstained with DAPI (blue) to visualize cell nuclei. 
 
Fig 5. Distribution of the viral and cellular markers E4, L1, and MCM7 in the adjacent 
epithelium of a SCC from a KTR (patient 17, ear). The top pictures shows the scan of the tissue 
sections (H&E staining) of the SCC (left picture; scale bar: 500 μm) and its edge (right picture; 
scale bar: 1000 μm). In the lower panel, the same sections were stained using antibodies to E4 
(green) (middle picture) and serial sections were stained with antibodies to L1 (red) (right picture). 
The region shown corresponds to the red square highlighted in the H&E image. Scale bars: 50 μm). 
All sections were counterstained with DAPI (blue) to visualize cell nuclei. The inset in the lower 
left picture shows the cytopathic effects typical of a productive β-HPV infection (scale bar: 20 μm). 
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Table 1   Baseline characteristics of the study cohort of kidney transplant recipients (KTRs) 
Patients
Birth 
date
Tx date
Years after transplantation
Table 2   Beta HPV DNA  distribution in the 111 formalin fixed paraffin embedded (FFPE) blocks obtained from the 79 lesions of the kidney transplant recipients (KTRs)  cohort
Lesions BD n = 1
FFPE blocks n = 1
Whole 
Lesion 
Core Edge 
n = 51 n = 28 n = 32
Positive 43 25 26 5 1 1 1 5 6 1 17 8 8 11 5 6 8 6 5
Genotype not 
defined*
4/43 3/25 1/26 1/5 1/17 1/8 1/8 1/5 2/8 1/6
Negative 8 3 6 1 1 4 2 5 2 1 1
SK: Seborrheic keratosis; KA: Keratoacanthoma; BD: Bowen’s disease; BCC: Basal cell carcinoma; AK: Actinic keratosis; SCC: Squamous cell carcinoma. 
*: unspecified -HPV genotype (see M&M)
SCC n = 14
FFPE blocks n = 111 FFPE blocks n = 8 FFPE blocks n = 13 FFPE blocks n = 44 FFPE blocks n = 25 FFPE blocks n = 20
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Table 3   -HPV genotyping analysis of each FFPE block obtained from the four patients with lesions positive for the -HPV E4 and L1 proteins (IF-positives)
Patients
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25 5, 9
8, 14, 19 38, 75   
(E4/L1)
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Tx: transplant; Lag: years since transplantation; SK: Seborrheic keratosis; KA: Keratoacanthoma; BD: Bowen’s disease; BCC: Basal cell carcinoma; AK: Actinic keratosis ; SCC: Squamous cell carcinoma; 
WL: Whole Lesion; E: Edge; C: Core; E1: Edge 1; E2: Edge 2
†: -HPV genotype; Pos: unspecified -HPV genotype (see M&M)
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Table 3   (Continued)
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WL: Whole Lesion; E: Edge; C: Core; E1: Edge 1; E2: Edge 2
†: -HPV genotype; Pos: unspecified -HPV genotype (see M&M)
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